Stockscreener 앱 받기
9.85
5.46%
0.51
시간 외 거래:
9.78
-0.07
-0.71%
전일 마감가:
$9.34
열려 있는:
$9.3
하루 거래량:
176.08K
Relative Volume:
0.48
시가총액:
$85.72M
수익:
-
순이익/손실:
$-6.42M
주가수익비율:
-1.7585
EPS:
-5.6013
순현금흐름:
$-7.45M
1주 성능:
+11.55%
1개월 성능:
+56.23%
6개월 성능:
+345.70%
1년 성능:
-13.14%
1일 변동 폭
$9.105
$9.88
1주일 범위
$8.76
$10.19
52주 변동 폭
$1.80
$20.63
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
CRVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
9.85 | 84.33M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-12-05 | 개시 | H.C. Wainwright | Buy |
| 2024-09-18 | 개시 | Chardan Capital Markets | Buy |
| 2024-07-26 | 개시 | Morgan Stanley | Overweight |
| 2024-02-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
CervoMed Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
CervoMed 2025 Q2 Earnings Deepening Losses Amid Revenue Decline - AInvest
CervoMed Shares Business and Financial Updates Online - TipRanks
CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
CervoMed Reveals Neurologic Treatment Progress: Key Presentation at Major Growth Conference Next Week - Stock Titan
Is CervoMed Inc. stock overvalued or undervaluedDouble or triple returns - Jammu Links News
What is the risk reward ratio of investing in CervoMed Inc. stockUnmatched profit potential - Jammu Links News
What analysts say about CervoMed Inc. stockAchieve breakthrough financial results - Jammu Links News
When is CervoMed Inc. stock expected to show significant growthBreakthrough investment results - Jammu Links News
What are CervoMed Inc. company’s key revenue driversMaximize portfolio value with smart investment plans - Jammu Links News
What is CervoMed Inc. company’s growth strategyFree Stock Market Forecast Reports - Jammu Links News
Should I hold or sell CervoMed Inc. stock in 2025Amplify your gains with low-risk picks - Jammu Links News
What drives CervoMed Inc. stock priceExponential wealth increase - Jammu Links News
Is CervoMed Inc. a growth stock or a value stockHigh-yield trading alerts - Jammu Links News
Is it the right time to buy CervoMed Inc. stockBreakout stock performance - jammulinksnews.com
CervoMed Inc. (NASDAQ:CRVO) Surges 53%; Retail Investors Who Own 48% Shares Profited Along With Insiders - 富途牛牛
CervoMed Shares Surge After Promising Dementia Drug Trial Results - MSN
How volatile is CervoMed Inc. stock compared to the marketSwing Trade Updates For Consistent Profits - Jammu Links News
Leading vs lagging indicators on CervoMed Inc. performanceTrade Scanner With Buy Zone Alerts Flagged - metal.it
CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock - Stocktwits
CervoMed Inc. Forms Double Bottom Pattern — Eyes on BreakoutAlpha Driven Watchlist With Alerts Published - metal.it
CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains? - MSN
Sentiment Turns Positive on CervoMed Inc. — Reversal AheadReliable Alerts for Daily Stock Movers Released - metal.it
Canaccord Genuity raises CervoMed stock price target to $27 on improved approval odds - Investing.com Nigeria
CervoMed (CRVO) Target Price Increased Following Positive Drug T - GuruFocus
Published on: 2025-07-29 09:25:15 - metal.it
Canaccord Genuity raises CervoMed stock price target to $27 on improved approval odds By Investing.com - Investing.com South Africa
Will CervoMed Inc. Benefit From Broader Market BounceAI Powered High Return Stock Calls Dominate Watchlists - metal.it
CervoMed Announces 32-Week Data from RewinD-LB Trial - GlobeNewswire
CervoMed Inc. Company’s Quarterly Earnings Growth: What the Numbers SayInvestment Strategy With Predictable Gains Outlined - metal.it
CervoMed Announces Positive Phase 2b Trial Results - TipRanks
CRVO Stock Skyrockets: What’s Next? - StocksToTrade
CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock By Stocktwits - Investing.com India
CervoMed's Dementia Data Show Slowed Disease Progression - Benzinga
Why CervoMed Stock is Suddenly Booming - StocksToTrade
CRVO’s New Phase 2b Results: What’s Next? - timothysykes.com
CervoMed Shares Rise on Trial Data for Neflamapimod - 富途牛牛
How to monitor CervoMed Inc. with trend dashboardsFree News Based Entry Opportunity Alerts - Newser
CervoMed Stock Soars 63.36% on Positive Dementia Drug Trial Data - AInvest
Best data tools to analyze CervoMed Inc. stockBuy Candidate Summary Based on Fundamentals - Newser
CervoMed stock soars after positive dementia drug trial data By Investing.com - Investing.com Nigeria
CervoMed stock soars after positive dementia drug trial data - Investing.com Australia
Combining machine learning predictions for CervoMed Inc.Price Spike Prediction for Active Traders - Newser
How does CervoMed Inc. generate profit in a changing economyFree Stock Selection - Jammu Links News
Will CervoMed Inc. benefit from macro trendsAI Generated Buy/Sell Signal Forecast - Newser
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Ne - GlobeNewswire
Breakthrough: New Dementia Treatment Cuts Disease Progression Risk by 64% in Major Clinical Trial Success - Stock Titan
How to track smart money flows in CervoMed Inc.Forecast Model for Intraday Buy Signals - Newser
How CervoMed Inc. stock performs during market volatilityAI Trading Forecast Based on Big Data - Newser
Combining machine learning predictions for CervoMed Inc. Reliable Setup Screener with Low Risk - Newser
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):